These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 32083466)

  • 1. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
    Valcourt DM; Dang MN; Scully MA; Day ES
    ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer.
    Scully MA; Wilkins DE; Dang MN; Hoover EC; Aboeleneen SB; Day ES
    Mol Pharm; 2023 Aug; 20(8):3895-3913. PubMed ID: 37459272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Regulation of miR-34a and Notch Signaling in Triple-Negative Breast Cancer by Antibody/miRNA Nanocarriers.
    Valcourt DM; Day ES
    Mol Ther Nucleic Acids; 2020 Sep; 21():290-298. PubMed ID: 32622330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
    Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
    Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.
    Li M; Chen F; Clifton N; Sullivan DM; Dalton WS; Gabrilovich DI; Nefedova Y
    Mol Cancer Ther; 2010 Dec; 9(12):3200-9. PubMed ID: 21159606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
    High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
    Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Light-inducible nanodrug-mediated photodynamic and anti-apoptotic synergy for enhanced immunotherapy in triple-negative breast cancer.
    Huang J; Liu X; Lin M; Xiao Z; Shuai X
    Biomater Sci; 2024 May; 12(10):2639-2647. PubMed ID: 38563394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TPGS nanoparticles co-loaded with ABT-737 and R848 for breast cancer therapy.
    Lang X; Wang X; Han M; Guo Y; Dong Z
    Biomed Pharmacother; 2024 Aug; 177():117107. PubMed ID: 38996708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing of Pyruvate Kinase M2
    Huang S; Zhu W; Zhang F; Chen G; Kou X; Yang X; Ouyang G; Shen J
    ACS Appl Mater Interfaces; 2021 Dec; 13(48):56972-56987. PubMed ID: 34797638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
    Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
    Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
    Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
    Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer.
    Sakakibara-Konishi J; Ikezawa Y; Oizumi S; Kikuchi J; Kikuchi E; Mizugaki H; Kinoshita I; Dosaka-Akita H; Nishimura M
    Int J Clin Oncol; 2017 Apr; 22(2):257-268. PubMed ID: 27816990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.
    Hiraki M; Suzuki Y; Alam M; Hinohara K; Hasegawa M; Jin C; Kharbanda S; Kufe D
    Sci Rep; 2016 May; 6():26643. PubMed ID: 27217294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
    Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
    Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
    Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
    Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.
    Wang S; Shao M; Zhong Z; Wang A; Cao J; Lu Y; Wang Y; Zhang J
    Drug Deliv; 2017 Nov; 24(1):1791-1800. PubMed ID: 29172759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indole-2-Carboxamide Derivative LG25 Inhibits Triple-Negative Breast Cancer Growth By Suppressing Akt/mTOR/NF-κB Signalling Pathway.
    Xu X; Rajamanickam V; Shu S; Liu Z; Yan T; He J; Liu Z; Guo G; Liang G; Wang Y
    Drug Des Devel Ther; 2019; 13():3539-3550. PubMed ID: 31631978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
    Stauffer SR
    Curr Top Med Chem; 2007; 7(10):961-5. PubMed ID: 17508927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.